Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Other Operating Expenses (2016 - 2026)

Ocular Therapeutix has reported Other Operating Expenses over the past 14 years, most recently at $17.9 million for Q1 2026.

  • For Q1 2026, Other Operating Expenses rose 16.2% year-over-year to $17.9 million; the TTM value through Mar 2026 reached $63.0 million, up 23.23%, while the annual FY2025 figure was $60.5 million, 28.13% up from the prior year.
  • Other Operating Expenses for Q1 2026 was $17.9 million at Ocular Therapeutix, up from $14.6 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $17.9 million in Q1 2026 and troughed at $10.4 million in Q1 2022.
  • A 5-year average of $12.7 million and a median of $12.0 million in 2023 define the central range for Other Operating Expenses.
  • Biggest five-year swings in Other Operating Expenses: fell 7.91% in 2023 and later surged 36.25% in 2025.
  • Year by year, Other Operating Expenses stood at $11.5 million in 2022, then fell by 7.91% to $10.6 million in 2023, then grew by 13.54% to $12.1 million in 2024, then rose by 20.56% to $14.6 million in 2025, then increased by 23.06% to $17.9 million in 2026.
  • Business Quant data shows Other Operating Expenses for OCUL at $17.9 million in Q1 2026, $14.6 million in Q4 2025, and $14.9 million in Q3 2025.